Neurofibromatosis type 2 (NF2)
Research & Innovation
The Neurofibromatosis Program at Children’s Hospital Boston is one the few sites that’s part of a national neurofibromatosis (NF) clinical trials consortium. This means that any new clinical trials opening in the area of NF1 or NF2 will involve our program here at Children’s.
We’re moving into a whole new era of medicine that features targeted treatments for individuals with NF2. For the first time these treatments, as part of clinical trials, will be available in children.
There is also a national NF clinical trial consortium, funded by the U.S. Department of Defense, that includes some of the largest NF centers throughout the country, both for NF1 and NF2. The goal of this consortium is to create targeted treatments for the various types of tumors accompanying NF and related disorders.
If you’d like to find out more about our clinical trials or see whether your child might be a candidate, please talk to your child’s doctor or email us at firstname.lastname@example.org.